Search results
Results from the WOW.Com Content Network
[2] [6] [4] Treatment may include restarting the medication and slowly decreasing the dose. [2] People may also be switched to the long-acting antidepressant fluoxetine which can then be gradually decreased. [6] Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome.
Because of their side effects and interaction risk, most MAOIs have been replaced by newer antidepressants over the years. In some cases, MAOIs may be prescribed to treat depression when newer ...
Discontinuation syndrome, which resembles recurrent depression in the case of the SSRI class, may occur after stopping the intake of any antidepressant [12] [13] Research regarding the effectiveness of antidepressants for depression in adults is controversial and has found both benefits [ 14 ] and drawbacks. [ 15 ]
Less common side effects of bicalutamide monotherapy in men include sexual dysfunction, depression, fatigue, weakness, and anemia. Bicalutamide is well tolerated and has few side effects in women. General side effects of bicalutamide that may occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash.
Rebound depression may appear to arise in patients previously free of such an illness. [2] Daytime rebound effects of anxiety, metallic taste, perceptual disturbances which are typical benzodiazepine withdrawal symptoms can occur the next day after a short-acting benzodiazepine hypnotic wears off. Rebound phenomena do not necessarily only occur ...
The risk factors [110] for treatment resistant depression are: the duration of the episode of depression, severity of the episode, if bipolar, lack of improvement in symptoms within the first couple of treatment weeks, anxious or avoidant and borderline comorbidity and old age. Treatment resistant depression is best handled with a combination ...
The treatment of a major depressive episode can be split into three phases: [27] Acute phase: the goal of this phase is to resolve the current major depressive episode. Continuation: this phase continues the same treatment from the acute phase for 4–8 months after the depressive episode has resolved, and the goal is to prevent relapse.
A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. [49]